These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 30683761

  • 21. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
    Casey JL, Pedley RB, King DJ, Green AJ, Yarranton GT, Begent RH.
    Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
    [Abstract] [Full Text] [Related]

  • 22. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
    Postema EJ, Börjesson PK, Buijs WC, Roos JC, Marres HA, Boerman OC, de Bree R, Lang M, Munzert G, van Dongen GA, Oyen WJ.
    J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
    [Abstract] [Full Text] [Related]

  • 23. Radiotherapy for isolated recurrent epithelial ovarian cancer: A single institutional experience.
    Komura N, Mabuchi S, Isohashi F, Yokoi E, Shimura K, Matsumoto Y, Kodama M, Tomimatsu T, Ogawa K, Kimura T.
    J Obstet Gynaecol Res; 2019 Jun; 45(6):1173-1182. PubMed ID: 30843318
    [Abstract] [Full Text] [Related]

  • 24. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
    Alvarez RD, Huh WK, Khazaeli MB, Meredith RF, Partridge EE, Kilgore LC, Grizzle WE, Shen S, Austin JM, Barnes MN, Carey D, Schlom J, LoBuglio AF.
    Clin Cancer Res; 2002 Sep; 8(9):2806-11. PubMed ID: 12231520
    [Abstract] [Full Text] [Related]

  • 25. Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125.
    Muto MG, Finkler NJ, Kassis AI, Howes AE, Anderson LL, Lau CC, Zurawski VR, Weadock K, Tumeh SS, Lavin P.
    Gynecol Oncol; 1992 Jun; 45(3):265-72. PubMed ID: 1612502
    [Abstract] [Full Text] [Related]

  • 26. Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy.
    Behr TM, Memtsoudis S, Sharkey RM, Blumenthal RD, Dunn RM, Gratz S, Wieland E, Nebendahl K, Schmidberger H, Goldenberg DM, Becker W.
    Int J Cancer; 1998 Aug 31; 77(5):787-95. PubMed ID: 9688314
    [Abstract] [Full Text] [Related]

  • 27. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W.
    Cancer Res; 1999 Jun 01; 59(11):2635-43. PubMed ID: 10363986
    [Abstract] [Full Text] [Related]

  • 28. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer.
    Molthoff CF, Pinedo HM, Schlüper HM, Nijman HW, Boven E.
    Br J Cancer; 1992 May 01; 65(5):677-83. PubMed ID: 1586596
    [Abstract] [Full Text] [Related]

  • 29. Tumor cure probability during alpha-RIT of ovarian cancer with different radiation sensitivity.
    Elgqvist J, Johansson BR, Partheen K, Danielsson A.
    Anticancer Res; 2010 Jul 01; 30(7):2545-51. PubMed ID: 20682981
    [Abstract] [Full Text] [Related]

  • 30. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings.
    Behr TM, Béhé M, Sgouros G.
    Cancer Biother Radiopharm; 2002 Aug 01; 17(4):445-64. PubMed ID: 12396708
    [Abstract] [Full Text] [Related]

  • 31. A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma.
    Mahé MA, Fumoleau P, Fabbro M, Guastalla JP, Faurous P, Chauvot P, Chetanoud L, Classe JM, Rouanet P, Chatal JF.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3249s-3253s. PubMed ID: 10541371
    [Abstract] [Full Text] [Related]

  • 32. α-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10.
    Li HK, Sugyo A, Tsuji AB, Morokoshi Y, Minegishi K, Nagatsu K, Kanda H, Harada Y, Nagayama S, Katagiri T, Nakamura Y, Higashi T, Hasegawa S.
    Cancer Sci; 2018 Jul 01; 109(7):2302-2309. PubMed ID: 29952132
    [Abstract] [Full Text] [Related]

  • 33. Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis.
    Nicholson S, Gooden CS, Hird V, Maraveyas A, Mason P, Lambert HE, Meares CF, Epenetos AA.
    Oncol Rep; 1998 Jul 01; 5(1):223-6. PubMed ID: 9458326
    [Abstract] [Full Text] [Related]

  • 34. Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial.
    Delaloye AB, Antonescu C, Louton T, Kuhlmann J, Hagenbeek A.
    J Nucl Med; 2009 Nov 01; 50(11):1837-43. PubMed ID: 19837764
    [Abstract] [Full Text] [Related]

  • 35. Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer.
    Meredith R, You Z, Alvarez R, Partridge E, Grizzle W, LoBuglio A.
    Cancer Biother Radiopharm; 2012 Feb 01; 27(1):36-40. PubMed ID: 22239432
    [Abstract] [Full Text] [Related]

  • 36. High-dose whole abdominal and pelvic irradiation for treatment of ovarian carcinoma: long-term toxicity and outcomes.
    Firat S, Murray K, Erickson B.
    Int J Radiat Oncol Biol Phys; 2003 Sep 01; 57(1):201-7. PubMed ID: 12909234
    [Abstract] [Full Text] [Related]

  • 37. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.
    Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Wong TZ, Bigner DD.
    J Nucl Med; 2008 Jan 01; 49(1):30-8. PubMed ID: 18077533
    [Abstract] [Full Text] [Related]

  • 38. Quantification of activity by alpha-camera imaging and small-scale dosimetry within ovarian carcinoma micrometastases treated with targeted alpha therapy.
    Chouin N, Lindegren S, Jensen H, Albertsson P, Bäck T.
    Q J Nucl Med Mol Imaging; 2012 Dec 01; 56(6):487-95. PubMed ID: 23358400
    [Abstract] [Full Text] [Related]

  • 39. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, Sparks RB, Stabin MG, Witzig T, White CA.
    J Nucl Med; 2003 Mar 01; 44(3):465-74. PubMed ID: 12621016
    [Abstract] [Full Text] [Related]

  • 40. Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with (90)Y-biotin?
    Grana C, Bartolomei M, Handkiewicz D, Rocca P, Bodei L, Colombo N, Chinol M, Mangioni C, Malavasi F, Paganelli G.
    Gynecol Oncol; 2004 Jun 01; 93(3):691-8. PubMed ID: 15196866
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.